Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
1.190
+0.050 (4.39%)
At close: May 12, 2025, 4:00 PM
1.180
-0.010 (-0.84%)
After-hours: May 12, 2025, 7:16 PM EDT
Immuneering Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Immuneering stock have an average target of 15.33, with a low estimate of 12 and a high estimate of 21. The average target predicts an increase of 1,188.24% from the current stock price of 1.19.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Immuneering stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Buy | 1 | 1 | 1 | 0 | 0 | 1 |
| Hold | 3 | 3 | 3 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 3 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $25 → $21 | Buy | Maintains | $25 → $21 | +1,664.71% | May 7, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $13 | Strong Buy | Maintains | $13 | +992.44% | May 6, 2025 |
| Needham | Needham | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +908.40% | Apr 10, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $13 | Strong Buy | Maintains | $13 | +992.44% | Mar 24, 2025 |
| Needham | Needham | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +908.40% | Mar 21, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.91
from -2.04
EPS Next Year
-2.20
from -1.91
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 86.6M | ||
| Avg | n/a | n/a | 42.1M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.72 | -1.97 | -1.05 | ||
| Avg | -1.91 | -2.20 | -1.91 | ||
| Low | -2.26 | -2.52 | -2.70 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.